Brief: Mabion Signs Framework Deal With UK Pharmaceutical Company
21/10/2024 15:42
Oct 21 (Reuters) - Mabion SA MABP.WA :
* SIGNS FRAMEWORK AGREEMENT WITH UK PHARMACEUTICAL COMPANY
* AGREEMENT INCLUDES GMP PROCESS DEVELOPMENT AND QUALITY
CONTROL
* AGREEMENT TERM IS 5 YEARS FROM SIGNING DATE
Source text for Workspace: ID:nEM9Gm1H1a
Further company coverage: MABP.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects